Publications Archives - Page 2 of 3 - Alzheon | Preserving Future Memories

3 Aug, 2018

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation In Human Brain

alzheon2024-06-19T16:49:25-04:00August 3rd, 2018|

25 Jul, 2018

Clinical Benefits of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses from the Phase 3 North American Trial

alzheon2019-09-23T12:10:47-04:00July 25th, 2018|

2 Nov, 2017

Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study

alzheon2019-09-23T12:10:48-04:00November 2nd, 2017|

23 Oct, 2017

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

alzheon2019-09-23T12:10:48-04:00October 23rd, 2017|

17 Jul, 2017

ALZ-801 Mechanism of Action: Stoichiometry of Beta Amyloid Anti-Oligomer Effect, PK/PD, and Clinical Dose Selection for Confirmatory Phase 3 Program in Alzheimer’s Disease

alzheon2019-09-23T12:10:49-04:00July 17th, 2017|

22 Jun, 2017

Clinical Effects Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease Suggest Disease Modification Potential

alzheon2019-09-23T12:10:49-04:00June 22nd, 2017|

24 Apr, 2017

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data

alzheon2019-09-23T12:10:49-04:00April 24th, 2017|

29 Mar, 2017

ALZ-801 Brain Penetration, PK/PD Analyses And Clinical Dose Projection Form The Basis For Confirmatory Phase 3 Study In Alzheimer’s Disease

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

29 Mar, 2017

Tramiprosate Efficacy in APOE4 Homozygous Subjects with AD: Larger Effects in Mild Patient Subgroups

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

9 Dec, 2016

Phase 1 Program of ALZ-801, a Novel Prodrug of Tramiprosate with Improved Tolerability, Supports Bridging to Upcoming Phase 3 Program

alzheon2019-09-23T12:10:50-04:00December 9th, 2016|